Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Matt Posard

Premium

Matt Posard has joined the board of directors of Halozyme Therapeutics, a biopharmaceutical company. Posard is currently Illumina's senior vice president and general manager of translational and consumer genomics. He has worked for the San Diego-based array vendor since 2006, serving first as its vice president of global marketing and then later as vice president of global sales. Prior to joining Illumina, Posard held various marketing positions at Gen-Probe and Biosite.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.